← Back to Search

TheraPPP Pathway for Acute Respiratory Distress Syndrome (TheraPPP Trial)

N/A
Waitlist Available
Led By Ken Parhar, MD MSc
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months (after the post-implementation period)
Awards & highlights

TheraPPP Trial Summary

This trial is testing a new way to treat Hypoxemic respiratory failure (HRF) and Acute Respiratory Distress Syndrome (ARDS) that may improve patient outcomes.

Eligible Conditions
  • Acute Respiratory Distress Syndrome
  • Hypoxemic Respiratory Failure

TheraPPP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months (after the post-implementation period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months (after the post-implementation period) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ACCEPTABILITY Pathway Acceptability measured using the Theoretical Framework of Acceptability (TFA)
FEASIBILITY (Economic) Cost per safe ventilation day
FEASIBILITY (Fidelity) Fidelity of the intervention using a composite fidelity score
Secondary outcome measures
Days of safe ventilation
Days of safe ventilation for females
Length of Stay (LOS) (ICU, hospital) / the number of days that patients stay in the ICU and in hospital
+15 more

TheraPPP Trial Design

1Treatment groups
Experimental Treatment
Group I: TheraPPP PathwayExperimental Treatment1 Intervention
We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation. All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods. To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation. To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
790 Previous Clinical Trials
867,438 Total Patients Enrolled
Alberta Health servicesOTHER
157 Previous Clinical Trials
648,624 Total Patients Enrolled
Ken Parhar, MD MScPrincipal InvestigatorUniversity of Calgary

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning (TheraPPP) Pathway
Ken Kuljit Parhar, MD 2019. "Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning (TheraPPP) Pathway". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04070053.
~162 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top